The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
Ascentage hopes to become a new force in BTK.
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Tacti-004 is terminated for futility, and Immutep crashes 89%.
But there are no efficacy data, and the mechanism has a mountain to climb.
